Although the current clinical trials of CDK7 inhibitors are focused on solid tumours, these results highlight the potential for CDK7 inhibitors to combat blood cancers, particularly if combined with BH3-mimetics. Here, CDK7 is linked to hematopoietic and lymphoid system neoplasm.